Introduction
============

Intraductal papillary mucinous neoplasia of the pancreas (IPMN) is characterized by adenomatous proliferation of the pancreatic-duct epithelium and may involve the main pancreatic duct (MPD), the branch ducts (BD), or both 1). Accordingly, IPMNs are named after the structure from which they are derived and are classified into 3 groups: the MPD, branch duct, or mixed (when they originate from both the main duct and branch ducts).

Without exception, all cases of IPMN are considered to be potentially malignant [@JR542-1] [@JR542-2] and surgical resection of pancreatic lesions is recommended to prevent transformation into malignancy. In most cases, BD-IPMNs are benign, but there is a 15 % risk of invasive carcinoma [@JR542-3] [@JR542-4] [@JR542-5] [@JR542-6] [@JR542-7] [@JR542-8]. Conversely, MPD- and mixed-IPMN cases are frequently malignant with a 50 % risk of invasive carcinoma [@JR542-9] [@JR542-10] [@JR542-11] [@JR542-12]. Until now, predictive factors for malignancy have not been fully defined and are still debated, even considering the consensus meeting held in 2012 [@JR542-2].

Many studies, including ours, have provided several clinical and imaging pre-therapeutic criteria for malignancy, which greatly influence the prognosis and mortality from IPMN, such as age (\> 70 years), presence of symptoms, a BD lesion with a diameter \> 3 cm, dilatation of the MPD, presence of mural solid nodules and/or thickening of a branch-duct cyst or the MPD wall, lymph nodes, peri-pancreatic extension, and positive cytology [@JR542-11] [@JR542-12] [@JR542-13] [@JR542-14]. The recent consensus divided these indications into "high-risk stigmata" and "worrisome features" [@JR542-2].

Taking into consideration that surgical resection of IPMN with a "malignancy signature" is the best-recommended treatment, the benefit -- risk ratio should be considered. Surgical intervention may include major pancreatic resection, such as the Whipple procedure, or total pancreatectomy, as is routinely used for multifocal lesions: these procedures have risks of mortality and morbidity of 0 % to 5 % and 30 % to 50 %, respectively [@JR542-15]. Therefore, in aged patients and/or patients with comorbidities, a preoperative diagnosis or a prediction of malignancy could be highly useful in current clinical practice.

Endoscopic ultrasound (EUS) is a highly sensitive imaging modality used to evaluate pancreatic cystic lesions. Assessment of cyst fluid for carcinoembryonic antigen (CEA) levels does not differentiate IPMN from mucinous cystic neoplasm and does not correlate with the degree of dysplasia or malignancy [@JR542-16] [@JR542-17] [@JR542-18].

Molecular pathology and genetic changes have been studied in IPMN and have shown that a point *KRAS*mutation is found in 48 % of benign cases of IPMN (low-grade or intermediate dysplasia) [@JR542-19] [@JR542-20]. *GNAS* mutations are present in 50 % to 64 % of cases of IPMN (predominantly of the intestinal subtype and to a lesser extent the gastric subtype) [@JR542-21] [@JR542-22] [@JR542-23] [@JR542-24]. Recent studies report that *GNAS* and/or *KRAS* mutations were found in 90 % of cases of IPMN [@JR542-24] [@JR542-25]. However, the role of *KRAS* and *GNAS* assays for the diagnosis of malignancy remains controversial and preliminary, taking into account that mutations of *KRAS* and *GNAS* were found in 50 % to 83 % and 25 % to 83 % of malignant IPMN, respectively [@JR542-19] [@JR542-23] [@JR542-24]. In other terms, whether DNA-based mutation assays are good biomarkers for predicting malignancy of IPMN remains to be demonstrated.

The aims of our study were to assess the role of pre-therapeutic cytopathology combined with *KRAS* and*GNAS* mutation assays within cystic fluid, sampled by EUS-FNA, to predict malignancy in a subgroup of patients with a likelihood of degenerative IPMN.

Patients and methods
====================

Patients and inclusion criteria
-------------------------------

Forty-one patients with BD, MPD-IPMN, or mixed-IPMN were prospectively enrolled between January 2010 and December 2014. A diagnosis of BD IPMN was established from radiologic criteria when unilocular or multilocular lesions with grapelike structures were observed communicating with the pancreatic ducts. In cases of mixed- or MPD-IPMN, MPD dilatation ≥ 5 mm was present in all patients. These imaging criteria were formerly identified (including communication between BD-cyst and MPD) from at least 2 morphologic examinations, including computed tomography (CT) scan, magnetic resonance cholangiopancreatography (MRCP), and EUS. 

We selected jaundice, acute pancreatitis, diabetes, BD dilatation \> 30 mm, mural-tissue component or thickening (branch-duct cyst or MPD wall), MPD size \> 10 mm, and lymph nodes as predictors of malignancy (i. e., a high likelihood of degenerative IPMN) as previously described [@JR542-1] [@JR542-10] [@JR542-11] [@JR542-13].

We excluded patients with IPMN and without clinical and/or imaging predictors of malignancy, a pancreatic cystic tumor that was different from IPMN, a solid pancreatic tumor, evidence of metastasis or a non-resectable pancreatic cystic tumor, and a contraindication to undergo an EUS-FNA.

Data, imaging, and EUS-FNA at inclusion
---------------------------------------

The clinical data recorded were age, gender, medical history, circumstances of diagnosis, and symptoms related to IPMN. All patients underwent helical triple-phase CT examinations and MRCP was performed in 81 % of patients [@JR542-8] [@JR542-11]. EUS-FNA procedures were performed, as previously described [@JR542-8] [@JR542-11] [@JR542-26] (Olympus GF-UC140 T echo-endoscope -- Hamburg, Germany). Data recorded at imaging were maximal diameter of the MPD and branch-duct cyst, the tissular component surrounding the MPD, mural modules and/or tissular thickening of the MPD and/or BD cyst wall (mainly at EUS), localization of BD lesions, and maximal diameter of the side-branch IPMN.

In each patient with predictor signs of malignancy, a fine-needle aspiration of cystic fluid was obtained using a Wilson Cook USN1 22G needle biopsy (Limerick, Ireland). All the cystic fluid was systematically sampled (with a collapse of cystic walls) and placed in a dry sterile tube for cytologic analysis (a minimum of 1 mL), except 500 to 750 microliters that was kept for molecular analyses. In cases where there was a mural nodule or a solid component within the IPMN, another FNA was systematically performed during the same procedure, using a different needle, in order to obtain tissue for a histologic microbiopsy (core biopsy). In cases where IPMN was resectioned, the pathology and IPMN histologic subtypes were assessed. The pathologic classification of IPMN was adopted in this work as follows: low-grade dysplasia, high-grade dysplasia, and invasive carcinoma [@JR542-1] [@JR542-2]. We considered malignant IPMN as having high-grade dysplasia and invasive carcinoma. In patients where an IPMN resection was not performed, clinical and biological follow-up were systematically conducted at least every 6 months (hospitalization or consultation), together with abdominal imaging (MRCP or CT) performed every 6 months for the first year, and then annually. In cases of clinical and/or radiologic evolution of IPMN, another EUS-FNA was performed.

For all patients, decisions on management were systematically made during a multidisciplinary meeting dedicated to pancreatic disease and that included at least 2 gastrointestinal surgeons, 2 gastroenterologists, an anesthesiologist, a pathologist and a radiologist. The regional platform committee for somatic genetics of tumors in the Midi-Pyrénées approved the protocol for the *KRAS*and*GNAS*assays from the EUS-FNA samples. Informed written and signed consent for investigations was obtained from each patient and the research was conducted in full accordance with ethical principles outlined in the Declaration of Helsinki.

*KRAS* and *GNAS* mutation assays
---------------------------------

The cystic fluid from IPMN was sampled using EUS-FNA: 500 -- 700-µL aliquots were placed in dry sterile 1-mL Eppendorf tubes, and were rapidly frozen at -- 20 °C until DNA was extracted. Samples were then centrifuged for 10 minutes at 8000 rpm. DNA was extracted from the pellets using a QIAamp DNA micro kit (QIAGEN-Les Ulis, France). Nucleic acids were quantified using a Nanovue spectrophotometer (GE Healthcare, Buckinghamshire, UK).

To identify *KRAS* exon 2, codon-12 mutations, we performed a mutation-detection assay based on custom TaqMan^®^ MGB™ dual probes (*KRAS*codon-12 mutations: c.34G \> C/p.G12R; c.35G \> A/p.G12D; c.35G \> T/p.G12V). Polymerase chain reaction (PCR) sequences were detected using 20 ng of genomic DNA, as previously described [@JR542-27]. The remaining DNA was subsequently used to assess *GNAS* mutations.

To identify the *GNAS* exon 8, codon-201 mutations, we performed a mutation-detection assay based on custom TaqMan^®^ MGB™ dual probes (GNAS codon-201 mutations: c.601C \> T/p.R201C and c.602G \> A/pR201H). Each probe incorporated a 5' reporter dye (VIC/FAM) specific to the WT or SNP sequence, and a 3' non-fluorescent quencher. Positive controls included DNA that was extracted from resected IPMN specimens and with known *GNAS* R201C and R201H mutations (sequencing). The negative control included DNA extracted from human pancreatic cancer cells (MiaPaca2 cells) with a known *GNAS* wild type [@JR542-28]. Amplification of the probe-specific product caused cleavage of the probe and generated an increase in reporter fluorescence. The use of a dual probe in each experiment made it possible to discriminate the signal for WT- and SNP-specific fluorescence in a single PCR and closed-tube format. Each alternation was screened with a dual-probe assay, with a wild-type and mutant for each of the 2 mutations screened. The runs were performed on a ROCHE LightCycler 480II (Roche Life Science, Boulogne-Billancourt, France) real-time PCR system. PCR was done in 10-µL reaction volumes that included 20 ng of genomic DNA and a 1X final master-mix custom Taqman^®^ SNP genotyping assay (Life Technologies, Gent, Belgium). The cycling condition was a 3-step PCR in 96-well plates, as follows: denaturation at 95 °C for 15 min, amplification for 40 cycles at 95 °C for 10 s, at 60 °C for 1 min, and then cooling at 40 °C for 30 s. Each run included positive and negative controls. Investigators who performed the *KRAS* and *GNAS*assays were blinded to the diagnoses.

Statistical analyses
--------------------

Results are expressed as mean ± SE. Qualitative and quantitative data were analyzed using Student's *t*-test, the chi-squared test, or Fisher's exact test, and Spearman's and Pearson's correlation tests, as appropriate, using GraphPad-Instat (version 3.1a) and GraphPad-Prims (version 6) software.

Results
=======

Patient characteristics and diagnoses
-------------------------------------

Among the 41 patients diagnosed with IPMN, 18 underwent surgical resection with confirmation of IPMN in all cases (a Whipple procedure in 9, a left pancreatectomy in 7, a total pancreatectomy in 2). Twenty-three patients did not undergo resection because 3 cases of IPMN displayed signs of unresectability at laparotomy, 3 patients refused surgery, and 17 patients had contraindications for pancreatic surgery because of age and/or multiple comorbidities, including concomitant extra-pancreatic carcinoma.

In the non-surgical group, 4 patients refused follow-up, so a diagnosis could not be confirmed. Among the 41 patients included, 37 could be analyzed (the flowchart for the study is shown in [Fig. 1](#FI542-1){ref-type="fig"}). [Table 1](#TB542-1){ref-type="table"} and [Table 2](#TB542-2){ref-type="table"} show the clinical, imaging, cytopathologic, and molecular characteristics at EUS-FNA of these 37 patients (men: 24; women: 13; mean age 69.5 years, median age 70 years). Half of the patients presented with at least 2 predictive signs of malignancy at diagnosis. No complication occurred during or after the EUS-FNA procedure. A final histologic diagnosis was obtained for all patients from resected specimens (n = 8) ([Table 1](#TB542-1){ref-type="table"}). For non-resected IPMN the final diagnosis was obtained ([Table 2](#TB542-2){ref-type="table"}): from biopsy tissue material obtained during a laparotomy (n = 3), from core biopsy at initial EUS-FNA (n = 12) and/or subsequent follow-up with second biopsy (EUS- or CT-guided) and occurrence of metastasis in case of malignant IPMN. On the whole, all 19 patients with non-resected IPMN were followed up after diagnosis (median 13 months, range 4 -- 60). In 8 patients with invasive carcinoma or high-grade dysplasia at baseline FNA (n = 6), or who had a surgical biopsy during laparotomy (n = 2) disease progressed both clinically and anatomically (median follow-up 7.5 months, deaths n = 5). In the 6 patients with no malignancy found on EUS-FNA (low-grade dysplasia or normal/hyperplasia), an invasive carcinoma was subsequently diagnosed based on clinical and/or imaging evidence (including a subsequent EUS-guided or CT-guided FNA with histologic analysis of a microbiopsy as well as a surgical biopsy during laparotomy): the median time to diagnosis of carcinoma was 8.5 months (range 2 -- 24) and there were 4 deaths. The 5 remaining patients did not have disease progression (median follow-up 52 months: range 14 -- 58 months), and this included 3 subsequent EUS-FNAs that still showed low-grade dysplasia. In these 5 patients, a diagnosis of benign IPMN was definitively attributed. Taking into account resected and non-resected IMPN, the final diagnoses were benign IPMN in 10 and malignant IPMN in 27 patients (i. e., 2with high-grade dysplasia; 25 with invasive carcinoma).

![ Flowchart of the study, including distribution of intraductal papillary mucinous neoplasia of the pancreas (IPMN) in patients depending on resection or not and the follow-up. IPMN with predictors of malignancy that indicated a high likelihood of malignancy were: jaundice, branch-duct dilatation \> 30 mm, a mural-tissue component, dilatation of the main pancreatic duct \> 10 mm, or lymph nodes. Malignant IPMN means high-grade dysplasia and invasive carcinoma; benign IPMN means low-grade dysplasia.](10-1055-s-0042-117216-i542ei1){#FI542-1}

###### Clinical, anatomical, and molecular characteristics, and pathologic findings in patients with resected branch-duct (BD)-, mixed-, or main pancreatic duct (MPD) intraductal papillary mucinous neoplasia of the pancreas (IPMN).

  ---------------------------------------------------------------------------------------------------------------------------------
  \#   Sex   Age   signs         Type    BD size\   MPD size\   Site   Cytopathology\   *KRAS*\   *GNAS*\   Final histology\
                                         (mm)       (mm)               at EUS-FNA       status    status    and diagnosis
  ---- ----- ----- ------------- ------- ---------- ----------- ------ ---------------- --------- --------- -----------------------
   1   M     62    Pain          Mixed   27          6          Head   Normal           G12 D     R201C     IC, gastric

   2   W     75    None          Mixed   60          8          Head   Carcinoma        WT        WT        HGD pancreato-biliary

   3   M     58    Pain          Mixed   32         11          Head   Carcinoma        G12V      WT        IC, intestinal

   4   W     76    Diabetes      BD      35          3.5        Body   Carcinoma        G12V      WT        IC, intestinal

   5   W     71    None          Mixed    6         12          Head   Normal           WT        WT        IC, intestinal

   6   M     72    Pain          Mixed   70          8          Head   Carcinoma        WT        WT        IC, intestinal

   7   M     59    AP            Mixed   35          7          Head   Carcinoma        WT        WT        IC intestinal

   8   M     65    None          Mixed   25          6          Body   Carcinoma        G12V      WT        IC, intestinal

   9   W     80    None          Mixed   50          6          Tail   LGD              G12 D     WT        HGD, gastric

  10   M     57    None          Mixed   40          8          head   LGD              WT        WT        LGD, gastric

  11   M     61    AP            Mixed   40          5          head   Normal           G12 D     R201H     LGD, gastric

  12   W     72    Weight loss   BD      90          5          head   HGD              WT        R201H     IC, gastric

  13   W     66    None          Mixed   18          6          body   Carcinoma        WT        WT        IC, intestinal

  14   M     65    none          Mixed   33          6          head   Normal           G12V      R201H     IC, gastric

  15   M     68    Weight loss   Mixed   30          7          head   LGD              G12 D     R201C     LGD, intestinal

  16   M     77    Pain          Mixed   32         12          body   Normal           G12 D     WT        LGD, gastric

  17   M     62    Pain          Mixed   40          9          head   LGD              G12 D     WT        IC, pancreato-biliary

  18   M     70    AP            BD      25          3          head   LGD              G12 D     R201C     LGD, gastric
  ---------------------------------------------------------------------------------------------------------------------------------

IC: IPMN with invasive adenocarcinoma; HGD = high-grade dysplasia IPMN; LGD = intermediate or low-grade dysplasia IPMN; AP: acute pancreatitis; BD: branch duct IPMN; MD: main-duct IPMN; mixed: mixed IPMN. WT: wild-type.

###### Clinical, anatomic, and molecular characteristics, and pathologic findings of patients with non-resected branch-duct (BD)-, mixed-, or main pancreatic duct (MPD) intraductal papillary mucinous neoplasia of the pancreas (IPMN).

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  #\.   Gender   Age   Signs             Type    BD size (mm)   MPD size (mm)   Site   Cytopathology\   *KRAS*status   *GNAS*status   Final diagnosis\
                                                                                       at EUS-FNA                                     (assessment)
  ----- -------- ----- ----------------- ------- -------------- --------------- ------ ---------------- -------------- -------------- -------------------
   1    W        56    Pain              BD      30              4              Head   Carcinoma\       G12 D          WT             IC, gastric\
                                                                                       (cytology)                                     (surgical biopsy)

   2    M        73    Pain              BD      50              4              Head   Normal\          G12 D          WT             IC, intestinal\
                                                                                       (cytology)                                     (surgical biopsy)

   3    M        75    Pain              BD      60              4              Body   HGD\             WT             R201C          IC\
                                                                                       (core biopsy)                                  (surgical biopsy)

   4    W        82    Jaundice          Mixed   20             12              Body   HGD\             G12 D          WT             IC\
                                                                                       (core biopsy)                                  (follow-up)

   5    M        79    Weight loss       Mixed   30              7              Head   LGD\             G12V           WT             IC\
                                                                                       (core biopsy)                                  (follow-up)

   6    M        64    None              Mixed   33              8              Head   LGD\             G12V           WT             LGD\
                                                                                       (core biopsy)                                  (second biopsy)

   7    M        73    Jaundice          BD      35              3.5            Head   HGD\             G12 D          WT             IC, intestinal\
                                                                                       (core biopsy)                                  (follow -- up)

   8    M        78    Diabetes          BD      32              5              Head   LGD\             WT             WT             LGD\
                                                                                       (cytology)                                     (follow-up)

   9    M        67    None              Mixed   35              7              Head   Normal\          G12 D          WT             IC\
                                                                                       (cytology)                                     (follow-up)

  10    M        85    Jaundice          Mixed   40              8              Head   Normal\          G12V           WT             IC\
                                                                                       (cytology)                                     (follow-up)

  11    W        57    Pain              Mixed   75              6              Body   Normal\          G12 D          WT             IC\
                                                                                       (cytology)                                     (second biopsy)

  12    W        58    None              BD      50              3              Body   LGD\             WT             WT             LGD\
                                                                                       (core biopsy)                                  (follow-up)

  13    W        67    Pain              BD      30              4              Body   HGD\             G12 R          WT             IC\
                                                                                       (core biopsy)                                  (follow-up)

  14    W        78    None              BD      31              3              Body   LGD\             WT             WT             LGD\
                                                                                       (core biopsy)                                  (follow-up)

  15    M        64    Jaundice          Mixed   33              8              Head   Carcinoma\       WT             R201C          IC, intestinal\
                                                                                       (core biopsy)                                  (follow-up)

  16    W        70    Jaundice          Mixed   30              5              Head   LGD\             WT             WT             IC\
                                                                                       (cytology)                                     (follow-up)

  17    M        84    Pain              Mixed   60              6              Head   Normal\          WT             WT             LGD\
                                                                                       (core biopsy)                                  (second biopsy)

  18    M        67    Bowel obstruct.   Mixed   35             11              Body   Carcinoma\       G12 D          WT             IC, gastric\
                                                                                       (core biopsy)                                  (follow-up)

  19    M        78    None              Mixed   28              7              Head   Carcinoma\       G12 D          ND             IC\
                                                                                       (core biopsy)                                  (follow-up)
  -------------------------------------------------------------------------------------------------------------------------------------------------------

IC: IPMN with invasive adenocarcinoma; HGD = high-grade dysplasia IPMN; LGD = intermediate or low-grade dysplasia IPMN; AP: acute pancreatitis; BD: branch duct IPMN; MD: main-duct IPMN; mixed: mixed IPMN. WT: wild-type. For initial EUS-cytopathology the material obtained is detailed in parenthesis: cytology alone (cytology n = 7) or histology on core biopsies (core biopsy n = 12). For the final diagnosis the assessment is detailed in parenthesis: surgical biopsy during laparotomy, second biopsy (EUS- or CT-guided) and follow-up (subsequent occurrence of metastasis).

Cytopathology and yield of KRAS and GNAS assays at the baseline EUS-FNA
-----------------------------------------------------------------------

Cytology and/or histologic analysis of EUS-FNA materials are detailed in [Table 1](#TB542-1){ref-type="table"} and [Table 2](#TB542-2){ref-type="table"} for patients with confirmed IPMN and carcinoma (n = 11, 30 %), for IPMN with high-grade dysplasia (n = 4,11 %), and for IPMN with low-grade dysplasia and normal/hyperplasia (n = 22, 59 %). *KRAS* and a*GNAS* assays were possible in all cases except one because of insufficient DNA material for subsequent *GNAS-*mutation analysis after assessing *KRAS* status. [Fig. 2](#FI542-2){ref-type="fig"} shows the representative curve plots for wild-type and mutated *KRAS* and *GNAS* samples. The mean quantity of DNA extracted per sample was 269 ± 58 ng (min: 35 ng; max: 1660 ng). There was no statistical difference in terms of quantity of DNA extracted from the subgroups with wild-type (232 ± 73 ng) or mutated (290 ± 86 ng) *KRAS*and*GNAS*(*P* = 0.65), or between the 2 subgroups with malignant (250 ± 78 ng) or benign (288 ± 103 ng) IPMN at the final diagnosis (*P* = 0.85) (unpaired Student's *t* test). In addition, there was no correlation between the size of the BD-IPMN in which fluid samples had been made by EUS and the amount of extracted DNA (Pearson's and Spearman's correlation tests: 0.027 \< r \< 0.05, data not shown). This indicates that neither the presence of malignancy nor the size of the side-branch IPMN influenced the amount of DNA in the cystic fluid.

![ Representative chromatogram of TaqMan allelic discrimination analysis of G12 D *KRAS* and R201C *GNAS* mutations obtained from EUS-guided fine-needle cystic-fluid aspiration from intraductal papillary mucinous neoplasia of the pancreas (IPMN). Panels **a** and **c**: plots of a wild-type DNA sample; panels **b** and **d**: plots of mutated DNA samples with distinct curves generated by mutated and wild-type probes.](10-1055-s-0042-117216-i542ei2){#FI542-2}

Combination of cytopathology and the KRAS/GNAS mutation assays to predict IPMN malignancy
-----------------------------------------------------------------------------------------

Data on sensitivity, specificity, predictive values, overall accuracy of the cytopathology alone, the *KRAS* analysis alone, the *GNAS* analysis alone, and the combination of either 2 or 3 tests to diagnose malignant versus benign IPMN are detailed in [Table 3](#TB542-3){ref-type="table"}.

###### Performance of cystic fluid EUS-FNA, EUS-FNA and a *KRAS* assay, EUS-FNA and a *GNAS* assay, EUS-FNA and a *KRAS* plus a *GNAS* assay to diagnose malignant intraductal papillary mucinous neoplasia of the pancreas (IPMN) in 37 patients with clinical and/or radiologic predictors of malignancy.

                              Sensitivity (95 % CI)   Specificity (95 % CI)   PPV (95 % CI)     NPV (95 % CI)   Accuracy (95 % CI)
  --------------------------- ----------------------- ----------------------- ----------------- --------------- --------------------
  EUS-FNA                     55 (35 -- 94)           100 (69 -- 100)         100 (78 -- 100)   45 (24 -- 67)   66 (54 -- 96)
  *KRAS*                      66 (46 -- 83)            50 (18 -- 80)           78 (56 -- 92)    36 (12 -- 64)   61 (48 -- 92)
  *GNAS*                      19 (6 -- 38)             70 (34 -- 93)           62 (24 -- 91)    24 (10 -- 43)   61 (43 -- 87)
  EUS-FNA + *KRAS*            92 (75 -- 99)            50 (18 -- 81)           83 (66 -- 93)    71 (29 -- 96)   81 (67 -- 96)
  EUS-FNA + *GNAS*            62 (42 -- 80)            70 (34 -- 93)           85 (62 -- 96)    41 (18 -- 67)   64 (37 -- 83)
  EUS-FNA + *KRAS* + *GNAS*   92 (75 -- 99)            50 (18 -- 81)           83 (66 -- 93)    71 (29 -- 96)   81 (67 -- 96)

PPV: positive predictive value; NPV: negative predictive value; EUS-FNA: endoscopic ultrasound-fine-needle guided aspiration.

We observed that combining cytopathologic analysis and the *KRAS*mutation assay increased the sensitivity (from 53 to 92 %), the negative predictive value (NPV) (from 45 to 71 %), and the accuracy (from 66 to 81 %) compared to cytopathology alone to diagnose malignant IPMN. This was not observed when using the combined cytopathologic analysis and *GNAS*-mutation assay. In addition, combining the cytopathology and *KRAS* and *GNAS* assays did not improve the performance of combining cytopathology and the *KRAS* assay. In [Table 4](#TB542-4){ref-type="table"} we compared the performances of cytopathology alone and the combination of cytopathology plus *KRAS*status in the 2 subgroups of patients that did or did not undergo resection of their IPMN. In these 2 subgroups, the sensitivity, the NPV, and the accuracy of cytopathology alone to diagnose IPMN malignancy were also increased when they were combined with the cystic fluid *KRAS-*mutation assay. Overall, we can conclude that when the EUS-FNA cytopathology and *KRAS* mutation assay are combined we can predict a malignancy in 80 % of cases of IPMN.

###### Performance of cystic fluid EUS-FNA and EUS-FNA plus a *KRAS* assay to diagnose malignant intraductal papillary mucinous neoplasia of the pancreas (IPMN) in two subgroups of patients with and without resection of IPMN and pre-therapeutic clinical and/or radiologic predictors of malignancy.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
                                   **Sensitivity (95 % CI)**   **Specificity (95 % CI)**   **PPV (95 % CI)**   **NPV (95 % CI)**   **Accuracy (95 % CI)**
  -------------------------------- --------------------------- --------------------------- ------------------- ------------------- ------------------------
  *Resected IPMN*(n = 18)\          \                           \                           \                   \                   \
   EUS-FNA\                        61 (31 -- 86)\              100 (47 -- 100)\            100 (63 -- 100)\    50 (18 -- 81)\      72 (48 -- 91)\
   EUS-FNA + *KRAS*                91(61 -- 99)                 33 (4 -- 77)                73 (44 -- 92)      66 (9 -- 99)        72 (43 -- 99)

  *Non-resected IPMN*(*n* = 19)\    \                           \                           \                   \                   \
   EUS-FNA\                        50 (23 -- 76)\              100 (47 -- 100)\            100 (59 -- 100)\    42 (15 -- 72)\      63 (45 -- 87)\
   EUS-FNA + *KRAS*                78 (49 -- 95)                80 (28 -- 99)               92 (61 -- 99)      57 (18 -- 90)       79 (52 -- 99)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

PPV: positive predictive value; NPV: negative predictive value; EUS-FNA: endoscopic ultrasound-fine-needle guided aspiration. There is no statistical difference in term of sensitivity and specificity between the two groups (resected versus non-resected -- 0.65 \< P \< 0.73, Fischer's exact test) except for the specificity of EUS-FNA + KRAS that was statistically lower in the resected group (*P* = 0.002).

Discussion
==========

In this prospective study, we investigated a subgroup of IPMN patients who had clinical predictors of malignancy assessed at diagnosis. We demonstrated that when the *KRAS-*mutation analysis was added to the cytopathology data from EUS-FNA materials, this improved the ability to diagnose malignancy. This is of importance as it will improve our ability to identify patients with high-grade dysplasia or invasive malignant IPMN and who might benefit from surgical resection. We also observed that testing for the *GNAS* mutation did not improve the performance of cytopathology alone or the combination of cytopathology plus the *KRAS* assay to diagnose this indication.

As previously observed in solid tumors, despite the paucity of material collected for molecular analysis from IPMN cystic fluid, which rarely excesses 500 µl, DNA extraction can be performed in 100 % of cases [@JR542-27]. Use of an extraction micro-kit enables this success rate. The amount of DNA was half that observed from EUS-FNA materials from solid pancreatic tumors [@JR542-27]. In addition, the amount of DNA was not influenced by the mutational status, the size of the cyst or its stage. To our knowledge, this study demonstrates, for the first time, that TaqMan allelic discrimination is feasible on material collected from pancreatic cystic fluid to assess both *KRAS*and *GNAS* mutation status.

As already observed, cytopathology has a sensitivity of \~50 % (with high specificity) in in diagnosing malignancy of IPMN [@JR542-16] [@JR542-17] [@JR542-18] but it is inferior to pre-therapeutic clinical imaging. In comparison, the codon-12 *KRAS* mutation assay alone had performance similar to that of cytopathology, with lower specificity and positive predictive value due to false-positive results (i. e., the presence of *KRAS* mutations in patients with low-grade dysplasia). However, when cytopathology and the *KRAS* assay are combined, sensitivity, NPV, and accuracy were substantially increased (sensitivity increased from 55 to 92 %, NPV from 45 % to 71 %, and accuracy from 66 % to 81 %). This indicates that associating cytopathology and testing *KRAS* in EUS-FNA material from IPMN may help predict malignancy in patients with BD or a mixed form of IPMN.

Conversely, the codon 201 *GNAS* mutation assay did not improve diagnosis. Moreover *GNAS* mutation (22 %, intestinal and gastric subtypes) appeared less frequently than previously observed in micro-dissected specimens of resected IPMN, in cystic fluid, or in duodenal fluid sampled under secretin stimulation (50 % -- 66 % of mutated *GNAS*) [@JR542-21] [@JR542-24] [@JR542-25] [@JR542-29]. Interestingly, when considering the subgroup of IPMN with high-grade dysplasia and invasive carcinoma, frequency of *GNAS* mutations ranges from 15 % -- 33 % and is found to be significantly less in cases of IPMN with invasive carcinoma when compared to other histopathologic grades [@JR542-24] [@JR542-25] [@JR542-30]. Regarding the current study, almost 75 % of patients with IMPN were diagnosed with high-grade dysplasia and invasive carcinoma. Such a patient population may account for the low frequency of *GNAS*mutations in our study.

A recent study from Tan et al., performed on micro-dissected IPMN tissues, did not find any significant difference in terms of *KRAS* or *GNAS* mutations according to the degree of dysplasia [@JR542-22]. However, *GNAS* mutations were more frequent in colloidal-type (89 %) than in tubular-type (32 %) invasive carcinoma, respectively [@JR542-22]. Conversely, *KRAS* mutations were significantly more frequent in the tubular-subtype (89 % vs. 52 %). In our work, almost 50 % of cases with resected IPMN and invasive carcinoma were either gastric or pancreatobiliary subtypes that generated adenocarcinoma with a tubular shape. Such an observation may also explain the low incidence of *GNAS* mutations in our series. Another explanation could be that cystic fluid sampled by EUS-FNA may contain only neoplastic cells from a limited area and does not reflect the entire pancreas, including the MPD. However, the frequency of *KRAS* mutations in our patient cohort was 62 %, an amount that is commonly found in IPMN tissues and fluid, including within high-grade or invasive cases [@JR542-23] [@JR542-24] [@JR542-25].

From a clinical point of view, allelic discrimination assays for *KRAS* mutations are currently performed on somatic genetic tumors in colon cancer specimens, thus this approach now can be readily transferred into routine clinical practice for pre-therapeutic evaluation of IPMN in EUS-FNA material (and recently Next Generation Sequencing). When treating patients with high-risk of stigmata, EUS-FNA associated with a *KRAS* mutation assay could be useful when making therapeutic decisions [@JR542-30]. From our results, in cases of high-grade dysplasia, combining cytopathology and/or *KRAS-*mutation assessment enabled prediction of malignancy in 80 % of cases. Recent studies have underscored the importance of combining both clinical and radiologic findings to assessment of hotspots mutations of pancreatic cyst fluid for detection of advanced neoplasia, especially IPMN [@JR542-31] [@JR542-32].

From a practical point of view, payment for additional molecular analysis can be an issue. In our study, only 9 of 37 patients (24 %) had a normal or LGD cytology at EUS with mutated *KRAS* and a final diagnosis of invasive carcinoma arising in the IPMN. Therefore, we would suggest reserving *KRAS* mutation analysis for cases with normal or non-contributive or LGD cytopathology (keeping thus a minimum 500 microliters of cystic fluid to a possible subsequent molecular analysis).

In addition, following the international consensus for IPMPN, Crippa et al. recently reported some significant predictor signs of disease-specific survival after multivariate analysis. They were age \> 70 years, presence of atypical or malignant cytology, jaundice, and main pancreatic duct size \> 15 mm [@JR542-2] [@JR542-33]. These data are important from a clinical point of view and, in our series, 54 % of patients (20 over 37) had at least 1 of these criteria. Besides the results of cytopathology after EUS-FNA, some of these criteria should be taken into account and finally *KRAS* mutation analysis also can be reserved for patients who meet longer survival criteria.

Conclusion
==========

In conclusion, in patients with a pre-therapeutic likelihood of IPMN-associated malignancy, use of EUS-FNA to obtain cystic fluid was safe, and the TaqMan allelic discrimination assay for *KRAS* and *GNAS* mutations was feasible. Although testing for *GNAS* mutations did not substantially improve diagnosis IPMN malignancy, the *KRAS* mutation assay, when combined with cytopathology, increased performance of cytopathology alone, especially in sensitivity, NPV, accuracy, and as a predictor of malignancy in 80 % of cases.
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